Empiric therapy for community acquired urinary tract infection in an era of increasing antimicrobial resistance

---

Original Article

Author Details : Bushra Anam*, Maimoona Mustafa, Iqra Anjum

Volume : 9, Issue : 4, Year : 2023

Article Page : 267-274

https://doi.org/10.18231/j.ijmmtd.2023.050

Suggest article by email

Get Permission

---

Abstract

Background: Community-acquired urinary tract infections (CA-UTIs) are widespread bacterial infections often necessitating empirical antibiotic therapy. However, the escalating antimicrobial resistance (AMR) poses a grave threat to treatment efficacy.
Aim: This study aims to assess the prevalence of AMR in uropathogens causing CA-UTIs and its implications for empirical therapy.
Materials and Methods: The study analyzed data from a tertiary care hospital, to determine AMR rates in common uropathogens, including Escherichia coli and Klebsiella pneumoniae. Resistance levels to key antibiotics, such as Ampicillin, Ciprofloxacin, and Norfloxacin, were evaluated.
Results: Significant resistance rates were observed in uropathogens, with Escherichia coli and Klebsiella pneumoniae showing marked resistance. Notably, resistance to commonly prescribed antibiotics like Ampicillin, Ciprofloxacin, and Norfloxacin was widespread, highlighting the severity of the AMR crisis.
Conclusion: The increasing AMR in CA-UTIs calls for a comprehensive approach. Strategies including local resistance pattern monitoring, antimicrobial stewardship programs and the recommendation of drugs like nitrofurantoin (with lower drug resistance potential) are crucial to maintain the effectiveness of empirical therapy. This study underscores the urgent need for collaborative efforts to address AMR, ensuring effective CA-UTI management and safeguarding public health.
 
Keywords: UTI, Urinary Tract Infection, Empirical Treatment, antimicrobial resistance, Nitrofurantoin

How to cite : Anam B, Mustafa M, Anjum I, Empiric therapy for community acquired urinary tract infection in an era of increasing antimicrobial resistance. IP Int J Med Microbiol Trop Dis 2023;9(4):267-274

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.